Bevacizumab in Metastatic Renal Cancer
NCT02627144
·
clinicaltrials.gov ↗
COMPLETED
Status
365
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Cell Cancer
Interventions
DRUG:
Bevacizumab
DRUG:
Interferon alpha-2a
Sponsor
Hoffmann-La Roche